Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from MaxCyte ( (MXCT) ).
MaxCyte, Inc. announced the issuance of 97,857 shares of common stock as part of its block admission facility, following the exercise of share options and vesting of restricted stock units. This brings the total issued stock capital to 106,416,389 shares, which shareholders can use to calculate their interest in the company. This move reflects MaxCyte’s ongoing efforts to support its operations and strengthen its market position in the cell-engineering sector.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell-engineering industry, focusing on providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics. The company has developed the ExPERT™ platform, based on Flow Electroporation® technology, to support the expanding cell therapy market, offering a range of instruments, processing assemblies, and software protocols.
For detailed information about MXCT stock, go to TipRanks’ Stock Analysis page.